Phase II Study of Ofatumumab in Combination With High Dose Methylprednisolone Followed by Ofatumumab and Lenalidomide Consolidative Therapy for the Treatment of Relapsed or Refractory CLL/SLL The HiLOG Trial

Trial Profile

Phase II Study of Ofatumumab in Combination With High Dose Methylprednisolone Followed by Ofatumumab and Lenalidomide Consolidative Therapy for the Treatment of Relapsed or Refractory CLL/SLL The HiLOG Trial

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Dec 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Methylprednisolone (Primary) ; Ofatumumab (Primary) ; Sargramostim
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Acronyms HiLOG
  • Most Recent Events

    • 08 Dec 2017 Planned End Date changed from 1 Jun 2019 to 1 Dec 2019.
    • 28 Jul 2017 Planned End Date changed from 1 Oct 2017 to 1 Jun 2019.
    • 28 Jul 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top